Fig. 5: Predicted HMO-utilization pathways that enable B. breve to benefit from priority effects. | The ISME Journal

Fig. 5: Predicted HMO-utilization pathways that enable B. breve to benefit from priority effects.

From: Priority effects shape the structure of infant-type Bifidobacterium communities on human milk oligosaccharides

Fig. 5

The HMO-utilization pathways, with LNFP I as a representative example, are shown for B. bifidum, B. infantis, and B. breve. Similar mechanisms are expected for other fucosylated HMOs. Activity, enzymes, and transporters attributable to B. bifidum are shown in blue, B. infantis in orange, and B. breve in green. Solid lines indicate assimilation by each species, round-dot lines indicate enzymatic degradation, and dashed lines indicate efflux. B. breve alone cannot assimilate LNFP I. a When B. breve is the prior colonizer, it is ready to utilize degradants as soon as they are made available by either B. bifidum or B. infantis. b When B. breve is the latter colonizer, most of the degradants are consumed before B. breve is introduced. LNT Lacto-N-tetraose; LNFP, Lacto-N-fucopentaose; LNTri II, Lacto-N-triose II, Fuc, Fucose; Glc, Glucose; GlcNAc, N-Acetylglucosamine; Gal, Galactose.

Back to article page